SAREPTA THERAPEUTICS, INC. Revenue
SAREPTA THERAPEUTICS, INC. (SRPT) reported Revenue of $401.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. revenues for the quarter ending 2026-06-30 was $401.25M, a 34.34% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. revenues for the quarter ending 2026-03-31 was $730.80M, a 1.89% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. revenues for the quarter ending 2025-12-31 was $442.93M, a 32.73% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. revenues for the quarter ending 2025-09-30 was $399.36M, a 14.52% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. revenues for fiscal 2025 was $2.20B, a 15.58% increase from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. revenues for fiscal 2024 was $1.90B, a 52.97% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. revenues for fiscal 2023 was $1.24B, a 33.26% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. revenues for fiscal 2022 was $933.01M, a 32.93% increase from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $401.25M 10-Q · filed 2026-08-05 | $1.13B 10-Q · filed 2026-08-05 | $1.57B derived: sum of 3 quarters · filed 2026-08-05 | $1.97B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $730.80M 10-Q · filed 2026-05-06 | $1.17B derived: sum of 2 quarters · filed 2026-05-06 | $1.57B derived: sum of 3 quarters · filed 2026-05-06 | $2.18B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $442.93M 10-K · filed 2026-03-02 | $842.29M derived: sum of 2 quarters · filed 2026-03-02 | $1.45B derived: sum of 3 quarters · filed 2026-08-05 | $2.20B 10-K · filed 2026-03-02 |
| 2025-09-30 | $399.36M 10-K · filed 2026-03-02 | $1.01B derived: sum of 2 quarters · filed 2026-08-05 | $1.76B 10-Q · filed 2025-11-06 | $2.41B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $611.09M 10-Q · filed 2026-08-05 | $1.36B 10-Q · filed 2026-08-05 | $2.01B derived: sum of 3 quarters · filed 2026-08-05 | $2.48B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $744.86M 10-Q · filed 2026-05-06 | $1.40B derived: sum of 2 quarters · filed 2026-05-06 | $1.87B derived: sum of 3 quarters · filed 2026-05-06 | $2.23B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $658.41M 10-K · filed 2026-03-02 | $1.13B derived: sum of 2 quarters · filed 2026-03-02 | $1.49B derived: sum of 3 quarters · filed 2026-03-02 | $1.90B 10-K · filed 2026-03-02 |
| 2024-09-30 | $467.17M 10-K · filed 2026-03-02 | $830.10M derived: sum of 2 quarters · filed 2026-03-02 | $1.24B 10-Q · filed 2025-11-06 | $1.64B derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $362.93M 10-K · filed 2026-03-02 | $776.39M 10-Q · filed 2025-08-06 | $1.17B derived: sum of 3 quarters · filed 2026-03-02 | $1.50B derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $413.46M 10-K · filed 2026-03-02 | $810.25M derived: sum of 2 quarters · filed 2026-03-02 | $1.14B derived: sum of 3 quarters · filed 2026-03-02 | $1.40B derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $396.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $728.60M derived: sum of 2 quarters · filed 2026-03-02 | $989.84M derived: sum of 3 quarters · filed 2026-03-02 | $1.24B 10-K · filed 2026-03-02 |
| 2023-09-30 | $331.82M 10-Q · filed 2024-11-06 | $593.05M derived: sum of 2 quarters · filed 2024-11-06 | $846.55M 10-Q · filed 2024-11-06 | $1.10B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $261.24M 10-Q · filed 2024-08-07 | $514.74M 10-Q · filed 2024-08-07 | $773.16M derived: sum of 3 quarters · filed 2025-02-28 | $1.00B derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $253.50M 10-Q · filed 2024-05-01 | $511.93M derived: sum of 2 quarters · filed 2025-02-28 | $742.20M derived: sum of 3 quarters · filed 2025-02-28 | $975.68M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $258.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $488.70M derived: sum of 2 quarters · filed 2025-02-28 | $722.18M derived: sum of 3 quarters · filed 2025-02-28 | $933.01M 10-K · filed 2025-02-28 |
| 2022-09-30 | $230.27M 10-Q · filed 2023-11-01 | $463.76M derived: sum of 2 quarters · filed 2023-11-01 | $674.59M 10-Q · filed 2023-11-01 | $876.05M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $233.49M 10-Q · filed 2023-08-02 | $444.32M 10-Q · filed 2023-08-02 | $645.78M derived: sum of 3 quarters · filed 2024-02-28 | $835.18M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $210.83M 10-Q · filed 2023-05-02 | $412.29M derived: sum of 2 quarters · filed 2024-02-28 | $601.70M derived: sum of 3 quarters · filed 2024-02-28 | $765.79M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $201.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $390.87M derived: sum of 2 quarters · filed 2024-02-28 | $554.96M derived: sum of 3 quarters · filed 2024-02-28 | $701.89M 10-K · filed 2024-02-28 |
| 2021-09-30 | $189.41M 10-Q · filed 2022-11-02 | $353.50M derived: sum of 2 quarters · filed 2022-11-02 | $500.43M 10-Q · filed 2022-11-02 | $645.56M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $164.09M 10-Q · filed 2022-08-02 | $311.02M 10-Q · filed 2022-08-02 | $456.16M derived: sum of 3 quarters · filed 2022-08-02 | $600.08M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $146.93M 10-Q · filed 2022-05-04 | $292.07M derived: sum of 2 quarters · filed 2022-05-04 | $435.99M derived: sum of 3 quarters · filed 2022-05-04 | $573.36M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $145.14M 10-K · filed 2021-03-01 | $289.06M derived: sum of 2 quarters · filed 2021-11-03 | $426.43M derived: sum of 3 quarters · filed 2021-11-03 | $540.10M 10-K · filed 2023-02-28 |
| 2020-09-30 | $143.92M 10-Q · filed 2021-11-03 | $281.29M derived: sum of 2 quarters · filed 2021-11-03 | $394.96M 10-Q · filed 2021-11-03 | $495.07M derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $137.36M 10-Q · filed 2021-08-04 | $251.04M 10-Q · filed 2021-08-04 | $351.15M derived: sum of 3 quarters · filed 2021-08-04 | $450.19M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $113.67M 10-Q · filed 2021-05-05 | $213.79M derived: sum of 2 quarters · filed 2021-05-05 | $312.83M derived: sum of 3 quarters · filed 2021-05-05 | $407.50M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $100.11M 10-K · filed 2021-03-01 | $199.15M derived: sum of 2 quarters · filed 2021-03-01 | $293.82M derived: sum of 3 quarters · filed 2021-03-01 | $380.83M 10-K · filed 2022-03-01 |
| 2019-09-30 | $99.04M 10-K · filed 2021-03-01 | $193.71M derived: sum of 2 quarters · filed 2021-03-01 | $280.72M 10-Q · filed 2020-11-05 | $365.13M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $94.67M 10-K · filed 2021-03-01 | $181.68M 10-Q · filed 2020-08-05 | $266.09M derived: sum of 3 quarters · filed 2021-03-01 | $344.58M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $87.01M 10-K · filed 2021-03-01 | $171.43M derived: sum of 2 quarters · filed 2021-03-01 | $249.91M derived: sum of 3 quarters · filed 2021-03-01 | $323.44M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $84.42M 10-K · filed 2020-02-26 | $162.90M derived: sum of 2 quarters · filed 2020-02-26 | $236.43M derived: sum of 3 quarters · filed 2020-02-26 | $301.03M 10-K · filed 2021-03-01 |
| 2018-09-30 | $78.49M 10-K · filed 2020-02-26 | $152.01M derived: sum of 2 quarters · filed 2020-02-26 | $216.62M 10-Q · filed 2019-11-07 | $273.90M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $73.53M 10-K · filed 2020-02-26 | $138.13M 10-Q · filed 2019-08-07 | $195.41M derived: sum of 3 quarters · filed 2020-02-26 | $241.36M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $64.60M 10-K · filed 2020-02-26 | $121.88M derived: sum of 2 quarters · filed 2020-02-26 | $167.84M derived: sum of 3 quarters · filed 2020-02-26 | $202.85M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $57.28M 10-K · filed 2019-02-28 | $103.23M derived: sum of 2 quarters · filed 2019-02-28 | $138.24M derived: sum of 3 quarters · filed 2019-02-28 | $154.58M 10-K · filed 2020-02-26 |
| 2017-09-30 | $45.95M 10-K · filed 2019-02-28 | $80.97M derived: sum of 2 quarters · filed 2019-02-28 | $97.31M 10-Q · filed 2018-10-31 | $102.73M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $35.01M 10-K · filed 2019-02-28 | $51.35M 10-Q · filed 2018-08-08 | $56.77M derived: sum of 3 quarters · filed 2019-02-28 | |
| 2017-03-31 | $16.34M 10-K · filed 2019-02-28 | $21.76M derived: sum of 2 quarters · filed 2019-02-28 | ||
| 2016-12-31 | $5.42M 10-K · filed 2018-03-01 | $5.42M 10-K · filed 2019-02-28 | ||
| 2015-12-31 | $1.25M 10-K · filed 2018-03-01 | |||
| 2014-12-31 | $9.76M 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |